6:33 PM
 | 
Dec 17, 2012
 |  BC Extra  |  Company News

Jakavi likely to undergo full assessment in Germany

Germany's Institute for Quality and Efficiency in Health Care (IQWiG) and Novartis AG (NYSE:NVS; SIX:NOVN) both estimate that Orphan drug Jakavi ruxolitinib will cost the German statutory health insurance funds (GKV) more than EUR...

Read the full 160 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >